3 Results for "

SGK1-IN-3

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "SGK1-IN-3" in MCE Product Catalog:

Cat. No.: HY-142686
CAS No.: 2891696-18-5
Target:  

SGK P-glycoprotein CDK

Research Areas:  

Inflammation/Immunology

SGK1-IN-3 (Compound 3a) is an ATP-competitive SGK1 inhibitor with an IC50 of <1 nM against hSGK1. SGK1-IN-3 blocks the activity of CDK family members. SGK1-IN-3 is a P-glycoprotein substrate. SGK1-IN-3 can be used for research on osteoarthritis .
loading...
    loading...
Cat. No.: HY-142686A
Purity:  96.65%
Target:  

SGK CDK P-glycoprotein

Research Areas:  

Inflammation/Immunology

SGK1-IN-3 hydrochloride (Compound 3a) is an ATP-competitive SGK1 inhibitor with an IC50 of <1 nM against hSGK1. SGK1-IN-3 hydrochloride blocks the activity of CDK family members. SGK1-IN-3 hydrochloride serves as a P-glycoprotein substrate. SGK1-IN-3 can be used for the research of osteoarthritis .
loading...
    loading...
Cat. No.: HY-167832
CAS No.: 2059104-90-2
PT109 is an orally active, blood-brain barrier permeable multi-kinase inhibitor. By inhibiting PTBP1, PT109 promotes the switch of pyruvate kinase isoform from PKM2 to PKM1, thereby effectively inhibiting the proliferation and migration of glioblastoma multiforme and inducing its reprogramming into oligodendrocytes. PT109 also targets and regulates key signaling molecules such as JNK, SGK1, GSK3β to exert neuroprotective effects including promoting neurogenesis, inducing synapse formation and alleviating neuroinflammation. In Alzheimer's disease models, PT109 exhibits significant efficacy in improving spatial learning ability, along with excellent in vivo pharmacokinetic properties. PT109 can be used to investigate metabolic reprogramming of glioblastoma multiforme and neuroprotective mechanisms of Alzheimer's disease .
loading...
    loading...